Proteasome-Regulated ERBB2 and Estrogen Receptor Pathways in Breast Cancer

A major challenge to broadening oncology applications for inhibitors of the ubiquitin-proteasome system (UPS) is the identification of UPS-dependent cancer pathways predictive of tumors responsive to peptidomimetic inhibitors of its 20S core protease activity. To inform clinical studies evaluating UPS inhibitors as breast cancer therapeutics, seven phenotypically diverse human breast cancer cell line models were characterized for their cellular and molecular responses to the clinically approved 20S inhibitor bortezomib (PS341; Velcade), focusing on those overexpressing estrogen receptor (ER) or ERBB2/HER2, because these oncogenic receptor pathways are constitutively activated in ∼80% of all breast cancers. All models demonstrated dose-dependent bortezomib reduction in intracellular 20S activity correlating with cell growth inhibition, and bortezomib IC50 values (concentrations producing 50% growth inhibition) varied directly with pretreatment 20S activities (r = 0.74; *, p < 0.05), suggesting that basal 20S activity may serve as a clinical predictor of tumor responsiveness to UPS inhibition. Reduction in 20S activity (> 60%) was associated with early (24 h) intracellular relocalization of ER (nucleus to cytoplasm) and ERBB2 (plasma membrane to perinuclear lysosomes), buildup of ubiquitinated and Hsp70-associated receptor, degradation and loss of ER and ERBB2 function, and induction of cellular apoptosis. These models were also used to screen a pharmacologic panel of pathway-targeted anticancer agents [4-hydroxy-3-methoxy-5-(benzothiazolylthiomethyl)benzylidenecyanoacetamide (AG825), 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide (AZD6244/ARRY142886), 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride (LY294002), 17-N-allylamino-17-demethoxy geldanamycin (17AAG), and (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (LAQ824)] for those capable of sensitizing to bortezomib. In keeping with the observation that 20S reduction has little effect on mitogen-activated protein kinase kinase 1/2 (MEK1/2) signaling in either ER-positive or ERBB2-positive models, only the MEK-1/2 inhibitor AZD6244 consistently improved the antitumor activity of bortezomib.

[1]  J. Cusack,et al.  NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model , 2006, Clinical Cancer Research.

[2]  T. Hunter,et al.  Proteasome inhibitor drugs on the rise. , 2006, Cancer research.

[3]  C. Benz,et al.  Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. , 2006, Assay and drug development technologies.

[4]  D. Esseltine,et al.  Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Pino,et al.  Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. , 2006, Cancer research.

[6]  D. Sawyer,et al.  Heat shock proteins in cancer: chaperones of tumorigenesis. , 2006, Trends in biochemical sciences.

[7]  B. Mellado,et al.  Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[8]  E. Dees,et al.  Targeting the ubiquitin-proteasome pathway in breast cancer therapy. , 2006, Future oncology.

[9]  R. Orlowski,et al.  The proteasome and proteasome inhibitors in cancer therapy. , 2006, Annual review of pharmacology and toxicology.

[10]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[11]  C. J. Barnes,et al.  Growth Factor Regulation of a 26S Proteasomal Subunit in Breast Cancer , 2005, Clinical Cancer Research.

[12]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[13]  M. Sliwkowski,et al.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.

[14]  S. Gillies,et al.  Use of Methotrexate-Based Peptide Substrates to Characterize the Substrate Specificity of Prostate-Specific Membrane Antigen (PSMA) , 2004, Cancer biology & therapy.

[15]  L. Neckers,et al.  Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. , 2004, Molecular cancer therapeutics.

[16]  D. Siegel,et al.  Regulation of NF-kB in multiple myeloma: therapeutic implications. , 2004, Clinical advances in hematology & oncology : H&O.

[17]  C. Sotiriou,et al.  Targeting the ubiquitin-proteasome pathway in breast cancer. , 2004, Clinical breast cancer.

[18]  J. Vance,et al.  The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress , 2003, Cell.

[19]  J. Ellenberg,et al.  Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. , 2003, Molecular cell.

[20]  Chawnshang Chang,et al.  Proteasome Activity Is Required for Androgen Receptor Transcriptional Activity via Regulation of Androgen Receptor Nuclear Translocation and Interaction with Coregulators in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[21]  C. Benz,et al.  Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. , 2002, Molecular cancer therapeutics.

[22]  T. Kohout,et al.  Regulation of Receptor Fate by Ubiquitination of Activated β2-Adrenergic Receptor and β-Arrestin , 2001, Science.

[23]  Y. Yarden,et al.  Sensitivity of Mature ErbB2 to Geldanamycin Is Conferred by Its Kinase Domain and Is Mediated by the Chaperone Protein Hsp90* , 2001, The Journal of Biological Chemistry.

[24]  T. Malek,et al.  The Proteasome Regulates Receptor-mediated Endocytosis of Interleukin-2* , 2001, The Journal of Biological Chemistry.

[25]  A. Goldberg,et al.  Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.

[26]  B. O’Malley,et al.  The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation , 2000 .

[27]  B. O’Malley,et al.  The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. , 2000, Molecular cell.

[28]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[29]  R. Kopito,et al.  Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.